Bajaj Healthcare Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.1 pts less than Nifty Microcap 250 and 10.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bajaj Healthcare reported revenue from operations of Rs 61,103 lakhs for FY2026, up 12.6% from Rs 54,260 lakhs in FY2025. However, profit after tax declined sharply to Rs 1,577 lakhs from Rs 3,950 lakhs in the prior year—a drop of about 60%. The sharp decline was primarily due to a Rs 3,325 lakh exceptional item: the company reversed income recognized in earlier years because a Middle East customer failed to meet committed timelines due to regional instability. The auditors issued an unmodified (clean) opinion on the financial statements. The board also recommended a final dividend of Rs 1.50 per share (30% on face value of Rs 5) for shareholder approval. Additionally, the company completed conversion of 20.79 lakh convertible warrants into equity shares at Rs 338 per share, raising Rs 5,271 lakhs.
The significant PAT decline due to the one-time exceptional charge could weigh on the stock price near-term. However, the underlying revenue growth and clean audit provide some comfort. The dividend recommendation offers some shareholder return support.